fbpx
QQQ
+ 1.70
362.90
+ 0.47%
DIA
+ 1.74
346.61
+ 0.5%
SPY
+ 2.34
435.25
+ 0.54%
TLT
-0.06
150.73
-0.04%
GLD
-0.19
169.80
-0.11%

Inovio's Manufacturing, Scalability Concerns Of Coronavirus Vaccine Keeps This Analyst On The Sidelines

June 30, 2020 8:37 pm
Share to Linkedin Share to Twitter Share to Facebook Share to Print License More
Inovio's Manufacturing, Scalability Concerns Of Coronavirus Vaccine Keeps This Analyst On The Sidelines

Inovio Pharmaceuticals Inc (NASDAQ:INO) reported Tuesday interim Phase 1 readout for INO-4800, its DNA vaccine candidate against the novel coronavirus.

The Inovio Analyst: Piper Sandler analyst Christopher Raymond maintained a Neutral rating and $8 price target for Inovio.

The Inovio Thesis: There wasn't a ton of detail at this point from the readout except that 94% or 34 of the 36 patients, demonstrating an "overall immunological" response at week 6, with a benign safety profile, Raymond said in a note. This appeared consistent with preclinical data published in May.

Raymond, however, said he would like to see data on neutralizing antibody production and T cell response generation separately and broken out by dose before drawing too many conclusions.

Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus newsletter.

The analyst expressed satisfaction with the safety data reported by Inovio.

"While initial human immunogenicity data is a necessary first step toward a viable COVID-19 vaccine, at this stage it's difficult (if not impossible) to determine which development candidate(s) will fare best in large-scale clinical trials," Raymond wrote in the note.

An equally important consideration is scalability.

The analyst is concerned over Inovio's dispute with its longtime manufacturing partner VGXI.

Investor hopes for INO-4800 to emerge as a viable vaccine candidate to address the current COVID-19 pandemic could prove unrealistic, barring clarity on the manufacturing scalability front, the analyst said.

Inovio Price Action: Inovio shares tumbled 14.9% to $26.95.

For the latest in financial news, exclusive stories, memes follow Benzinga on Twitter, Facebook & Instagram. For the best interviews, stock market talk & videos, subscribe to Benzinga Podcasts and our YouTube channel.


Related Articles

Inovio Has 'Bigger Value Drivers' Outside Of COVID-19 Vaccine Program: BofA Analyst

Inovio Pharmaceuticals, Inc. (NASDAQ: INO), which has fallen behind in the COVID-19 vaccine race, has much to offer beyond a coronavirus vaccine, according to a BofA Securities analyst.  read more

Inovio Shares Rally As Oppenheimer Says Coronavirus Vaccine Developer Approaching Finish Line

Shares of coronavirus vaccine developer Inovio Pharmaceuticals Inc (NASDAQ: INO) were surging Friday after a vote of confidence from the Street.  read more

Why This Inovio Analyst Is Reducing Estimates For The Coronavirus Vaccine Developer

Inovio Pharmaceuticals Inc (NASDAQ: INO) failed to inspire confidence among investors despite revealing in its second-quarter earnings report that it is on track for a September start for https://www.benzinga.com/general/biotech/20/08/17027473/the-daily-biotech-pulse-regulatory-setback-for-fennec-p read more

Inovio Analyst Downgrades COVID-19 Vaccine Developer, Says Risk Higher After Rally

Inovio Pharmaceuticals Inc (NASDAQ: INO) shares have rallied strongly in late June, moving from $14.27 on June 19 to $31.25 on July 25, translating to a stellar gain of about 110%. read more